Pfizer and Astellas have, this morning, announced that the addition of enzalutamide to standard androgen deprivation (ADT) has led to improved outcomes in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, ARCHES, deprivation, enzalutamide, hormone, outcome, sensitive, standard, trial | 2 Comments »
We have long been bedeviled by questions about some of the short- and the long-term side effects and complications of androgen deprivation therapy (ADT) in the treatment of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, Alzheimer's, androgen, dementia, deprivation, failure, heart, side effect | 2 Comments »
Most men who are taking androgen deprivation therapy (ADT) for metastatic prostate cancer feel the need to “do something” about their diet in order to (a) further help to control the risk for progression of their cancer and (b) help to cope with the side effects of ADT. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: ADT, adverse, androgen, deprivation, diet, effects, nutrition, side | 3 Comments »
A newly published article in the Journal of Urology has indicated risk of an association between treatment with androgen deprivation therapy (ADT) and risk for a spectrum of liver disorders. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, adverse, andogen, deprivation, disease, effect, fatty, liver, NAFLD, nonalcoholic | 4 Comments »
A new analysis of data from men treated for their prostate cancer between 1992 and 2009 has provided additional information with respect to risks for long-term side effects of androgen deprivation therapy (ADT). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: ADT, adverse, androgen, deprivation, effects, risk, side | 5 Comments »
